Metric Finance
LearnFAQ
LearnFAQ

Learn / CGON

NASDAQ: CGON

CG Oncology (CGON) stock, explained like you're 5

CG Oncology trades on the Nasdaq under the ticker CGON. It is a mid cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 5.7 billion dollars.

Ticker
CGON
Exchange
Nasdaq
Sector
Healthcare
Industry
Biological Products (No Diagnostic Substances)
Size
Mid cap, about 5.7 billion dollars

Is CG Oncology a small, medium or large cap company?

No. CG Oncology is a mid cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 5.7 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How CG Oncology makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves CGON stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • How Investors May Respond To CG Oncology (CGON) Hiring a CCO Before Potential Bladder Cancer Launch (Yahoo Finance)
  • A director plans to sell 3,000 shares of CG Oncology (NASDAQ: CGON). (Stock Titan)
  • CG Oncology (CGON) Names New Commercial Chief As Valuation Turns Back To Cretostimogene (Simply Wall Street)
  • CG Oncology Stock Gains 12% in Three Months: What's Driving It? (TradingView)
  • CGON Nov 2026 70.000 call (CGON261120C00070000) Stock Price, News, Quote & History (Yahoo! Finance Canada)

Follow CGON in your daily brief

Each trading day at 5 PM ET we post what happened to CG Oncology and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow CGON

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about CG Oncology stock

What does CG Oncology do?

CG Oncology trades on the Nasdaq under the ticker CGON. It is a mid cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 5.7 billion dollars.

What is the ticker symbol for CG Oncology?

CG Oncology trades under the ticker CGON on the Nasdaq.

What is CG Oncology's market cap?

CG Oncology is a mid cap stock with a market cap of about 5.7 billion dollars.

How does CG Oncology make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves CGON stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow CGON stock every day?

Add CGON to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow CGON daily

A free brief on CG Oncology and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • ARGX · Argenx SE
  • RVMD · Revolution Medicines
  • BNTX · BioNTech SE
  • EXEL · Exelixis

Similar stocks

  • ARGXArgenx SE
  • RVMDRevolution Medicines
  • BNTXBioNTech SE
  • EXELExelixis

Compare CGON: CGON vs ARGX, CGON vs RVMD, CGON vs BNTX

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed